A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

• Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
• Has received 1 or 2 prior lines of systemic therapy, including at least 1 prior platinum-based therapy. 
• Patients may have received prior PARPi, anti-PD-1/L1 or bevacizumab and these are not considered prior line of therapy
• Radiographic evidence of disease progression within 6 months after the lat dose of platinum-based chemo
• ECOG PS 0-1
• Radiographically evaluable disease (measurable or non-measurable)
• Cannot have primary platinum-refractory disease (defined as PD while actively receiving firstline platinum therapy)
• Cannot have uncontrolled hypertenstion, clinically relevant bowel obstruction, or rectosigmoid involvement of cancer
• Cannot have received more than 2 lines prior lines of systemic therapy
• No known active CNS metastases
• No known HIV/HBV/HCV

• Primary
  • PFS
• Secondary
  • OS
  • PFS by blinded central review
  • Safety
  • QOL